Drug news
CHMP recommends extension of Erbitux (Merck Serono) indication in Colorectal Cancer
The CHMP recommends extension of the label for Erbitux (cetuximab) from Merck Serono/BMS for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic Colorectal Cancer as first in line therapy with the FOLFOX chemotherapy in addition to its use in combination with irenotecan-based chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.